Any newly diagnosed patient should be referred to a multidisciplinary team experienced in the treatment of pituitary adenomas. The therapeutic management of acromegaly always requires a personalized strategy. Normal age-matched IGF-I values are the treatment goal. Transsphenoidal surgery by an expert neurosurgeon is the primary treatment modality for most patients, especially if there are neurological complications. In patients with poor clinical conditions or who refuse surgery, primary medical treatment should be offered, firstly with somatostatin analogs (SSAs). In patients who do not reach hormonal targets with first-generation depot SSAs, a second pharmacological option with pasireotide LAR or pegvisomant (alone or combined with SSA) should be offered. Irradiation could be proposed to patients with surgical remnants who would like to be free from long-term medical therapies or those with persistent disease activity or tumor growth despite surgery or medical therapy. Since the therapeutic tools available enable therapeutic targets to be achieved in most cases, the challenge is to focus more on the quality of life.

Italian Association of Clinical Endocrinologists (AME) and Italian AACE Chapter Position Statement for Clinical Practice: Acromegaly - Part 2: Therapeutic Issues / Cozzi, Renato; Ambrosio, Maria R.; Attanasio, Roberto; Bozzao, Alessandro; De Marinis, Laura; De Menis, Ernesto; Guastamacchia, Edoardo; Lania, Andrea; Lasio, Giovanni; Logoluso, Francesco; Maffei, Pietro; Poggi, Maurizio; Toscano, Vincenzo; Zini, Michele; Chanson, Philippe; Katznelson, Laurence. - In: ENDOCRINE, METABOLIC & IMMUNE DISORDERS. DRUG TARGETS. - ISSN 2212-3873. - 20:8(2020), pp. 1144-1155. [10.2174/1871530320666200129113328]

Italian Association of Clinical Endocrinologists (AME) and Italian AACE Chapter Position Statement for Clinical Practice: Acromegaly - Part 2: Therapeutic Issues

Alessandro Bozzao
Membro del Collaboration Group
;
Vincenzo Toscano;
2020

Abstract

Any newly diagnosed patient should be referred to a multidisciplinary team experienced in the treatment of pituitary adenomas. The therapeutic management of acromegaly always requires a personalized strategy. Normal age-matched IGF-I values are the treatment goal. Transsphenoidal surgery by an expert neurosurgeon is the primary treatment modality for most patients, especially if there are neurological complications. In patients with poor clinical conditions or who refuse surgery, primary medical treatment should be offered, firstly with somatostatin analogs (SSAs). In patients who do not reach hormonal targets with first-generation depot SSAs, a second pharmacological option with pasireotide LAR or pegvisomant (alone or combined with SSA) should be offered. Irradiation could be proposed to patients with surgical remnants who would like to be free from long-term medical therapies or those with persistent disease activity or tumor growth despite surgery or medical therapy. Since the therapeutic tools available enable therapeutic targets to be achieved in most cases, the challenge is to focus more on the quality of life.
2020
Acromegaly; aggressive; cabergoline; comorbidities; discrepant; gammaknife; neurosurgery; pasireotide; pegvisomant; pituitary; resistant; somatostatin analogs
01 Pubblicazione su rivista::01a Articolo in rivista
Italian Association of Clinical Endocrinologists (AME) and Italian AACE Chapter Position Statement for Clinical Practice: Acromegaly - Part 2: Therapeutic Issues / Cozzi, Renato; Ambrosio, Maria R.; Attanasio, Roberto; Bozzao, Alessandro; De Marinis, Laura; De Menis, Ernesto; Guastamacchia, Edoardo; Lania, Andrea; Lasio, Giovanni; Logoluso, Francesco; Maffei, Pietro; Poggi, Maurizio; Toscano, Vincenzo; Zini, Michele; Chanson, Philippe; Katznelson, Laurence. - In: ENDOCRINE, METABOLIC & IMMUNE DISORDERS. DRUG TARGETS. - ISSN 2212-3873. - 20:8(2020), pp. 1144-1155. [10.2174/1871530320666200129113328]
File allegati a questo prodotto
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/1689145
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? 2
  • Scopus 5
  • ???jsp.display-item.citation.isi??? 3
social impact